{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:11:02Z","timestamp":1793157062652,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"NIH Division of Loan Repayment","award":["L30DK144880"],"award-info":[{"award-number":["L30DK144880"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Surg Endosc"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00464-026-13147-z","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:25:55Z","timestamp":1784298355000},"page":"7973-7984","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evolving utilization of bariatric surgery since the rise of semaglutide and tirzepatide"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8965-9674","authenticated-orcid":false,"given":"Akio","family":"Kozato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhani S.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak J.","family":"Orandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan B.","family":"Massie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Mankowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Ren-Fielding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorry L.","family":"Segev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6620-8777","authenticated-orcid":false,"given":"Karan R.","family":"Chhabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"issue":"11","key":"13147_CR1","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S et al (2021) Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 384(11):989\u20131002. https:\/\/doi.org\/10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"},{"issue":"3","key":"13147_CR2","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN et al (2022) Tirzepatide once weekly for the treatment of obesity. N Engl J Med 387(3):205\u2013216. https:\/\/doi.org\/10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"issue":"24","key":"13147_CR3","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM et al (2023) Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 389(24):2221\u20132232. https:\/\/doi.org\/10.1056\/NEJMoa2307563","journal-title":"N Engl J Med"},{"issue":"2","key":"13147_CR4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P et al (2024) Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 391(2):109\u2013121. https:\/\/doi.org\/10.1056\/NEJMoa2403347","journal-title":"N Engl J Med"},{"issue":"12","key":"13147_CR5","doi-asserted-by":"publisher","first-page":"e70932","DOI":"10.1002\/cam4.70932","volume":"14","author":"K Parsons","year":"2025","unstructured":"Parsons K, Montalvo M, Fischbach N, Taylor M, Alfaro S, Lustberg M (2025) The Impact and safety of GLP-1 agents and breast cancer. Cancer Med 14(12):e70932. https:\/\/doi.org\/10.1002\/cam4.70932","journal-title":"Cancer Med"},{"key":"13147_CR6","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2026.0049","author":"SC Rohde","year":"2026","unstructured":"Rohde SC, Chao GF, Abdel-Rasoul M, Elsaid MI, Sweigert PJ (2026) Trends in metabolic and bariatric surgery use during the GLP-1 receptor agonist era. JAMA Surg. https:\/\/doi.org\/10.1001\/jamasurg.2026.0049","journal-title":"JAMA Surg"},{"key":"13147_CR7","unstructured":"American Society for Metabolic and Bariatric Surgery (n.d.) Estimate of bariatric surgery numbers, 2011\u20132023. https:\/\/asmbs.org\/resources\/estimate-of-bariatric-surgery-numbers\/. Accessed 7 Jan 2026"},{"issue":"10","key":"13147_CR8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.41380","volume":"7","author":"K Lin","year":"2024","unstructured":"Lin K, Mehrotra A, Tsai TC (2024) Metabolic bariatric surgery in the era of GLP-1 receptor agonists for obesity management. JAMA Netw Open 7(10):e2441380. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.41380","journal-title":"JAMA Netw Open"},{"issue":"14","key":"13147_CR9","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/ajhp\/zxae105","volume":"81","author":"EM Tichy","year":"2024","unstructured":"Tichy EM, Hoffman JM, Tadrous M et al (2024) National trends in prescription drug expenditures and projections for 2024. Am J Health Syst Pharm 81(14):583\u2013598. https:\/\/doi.org\/10.1093\/ajhp\/zxae105","journal-title":"Am J Health Syst Pharm"},{"key":"13147_CR10","unstructured":"KFF (2025) Poll: 1 in 8 adults say they are currently taking a GLP-1 drug for weight loss, diabetes or another condition, even as half say the drugs are difficult to afford. https:\/\/www.kff.org\/public-opinion\/poll-1-in-8-adults-say-they-are-currently-taking-a-glp-1-drug-for-weight-loss-diabetes-or-another-condition-even-as-half-say-the-drugs-are-difficult-to-afford\/"},{"issue":"10","key":"13147_CR11","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.18553\/jmcp.2021.27.10.1482","volume":"27","author":"S Blecker","year":"2021","unstructured":"Blecker S, Adhikari S, Zhang H et al (2021) Validation of EHR medication fill data obtained through electronic linkage with pharmacies. J Manag Care Spec Pharm 27(10):1482\u20131487. https:\/\/doi.org\/10.18553\/jmcp.2021.27.10.1482","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"13147_CR12","doi-asserted-by":"publisher","first-page":"e2457349","DOI":"10.1001\/jamanetworkopen.2024.57349","volume":"8","author":"PJ Rodriguez","year":"2025","unstructured":"Rodriguez PJ, Zhang V, Gratzl S et al (2025) Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity. JAMA Netw Open 8(1):e2457349. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.57349","journal-title":"JAMA Netw Open"},{"issue":"3","key":"13147_CR13","doi-asserted-by":"publisher","first-page":"e245586","DOI":"10.1001\/jamahealthforum.2024.5586","volume":"6","author":"JH Hwang","year":"2025","unstructured":"Hwang JH, Laiteerapong N, Huang ES, Kim DD (2025) Lifetime health effects and cost-effectiveness of tirzepatide and semaglutide in US adults. JAMA Health Forum 6(3):e245586. https:\/\/doi.org\/10.1001\/jamahealthforum.2024.5586","journal-title":"JAMA Health Forum"},{"issue":"3","key":"13147_CR14","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/oby.23952","volume":"32","author":"H Gasoyan","year":"2024","unstructured":"Gasoyan H, Pfoh ER, Schulte R, Le P, Rothberg MB (2024) Early- and later-stage persistence with antiobesity medications: a retrospective cohort study. Obesity Silver Spring 32(3):486\u2013493. https:\/\/doi.org\/10.1002\/oby.23952","journal-title":"Obesity Silver Spring"},{"key":"13147_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s00464-025-12403-y","author":"A Brown","year":"2025","unstructured":"Brown A, Patel SS, Li E et al (2025) Bariatric surgery vs. GLP-1 receptor agonists among primarily Medicare and Medicaid patients with diabetes: a 3-year analysis. Surg Endosc. https:\/\/doi.org\/10.1007\/s00464-025-12403-y","journal-title":"Surg Endosc"},{"key":"13147_CR16","unstructured":"Claxton G, Rae M, Winger A, et al. (2025) Employer health benefits 2025 annual survey. KFF"},{"key":"13147_CR17","unstructured":"Chuang IZ, Welliver S (2023) Designing fiscally viable coverage of GLP-1 weight-loss drugs. Mercer."},{"issue":"1","key":"13147_CR18","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41591-023-02669-x","volume":"30","author":"SW Waldrop","year":"2024","unstructured":"Waldrop SW, Johnson VR, Stanford FC (2024) Inequalities in the provision of GLP-1 receptor agonists for the treatment of obesity. Nat Med 30(1):22\u201325. https:\/\/doi.org\/10.1038\/s41591-023-02669-x","journal-title":"Nat Med"},{"issue":"12","key":"13147_CR19","doi-asserted-by":"publisher","first-page":"e214182","DOI":"10.1001\/jamahealthforum.2021.4182","volume":"2","author":"LA Eberly","year":"2021","unstructured":"Eberly LA, Yang L, Essien UR et al (2021) Racial, ethnic, and socioeconomic inequities in glucagon-like peptide-1 receptor agonist use among patients with diabetes in the US. JAMA Health Forum 2(12):e214182. https:\/\/doi.org\/10.1001\/jamahealthforum.2021.4182","journal-title":"JAMA Health Forum"},{"key":"13147_CR20","unstructured":"Williams E (2026) Medicaid Coverage of and Spending on GLP-1s | KFF. Published online January 16, 2026. https:\/\/www.kff.org\/medicaid\/medicaid-coverage-of-and-spending-on-glp-1s\/. Accessed 27 Feb 2026"},{"key":"13147_CR21","unstructured":"Wennberg JE, Wennberg DE (eds.) (2000) The problem of unwanted variations. In: The Dartmouth atlas of health care in Michigan. Chicago, IL: American Hospital Publishing."},{"issue":"8","key":"13147_CR22","doi-asserted-by":"publisher","first-page":"6032","DOI":"10.1007\/s00464-023-10030-z","volume":"37","author":"GF Chao","year":"2023","unstructured":"Chao GF, Lindquist K, Vitous CA et al (2023) A qualitative analysis describing attrition from bariatric surgery to identify strategies for improving retention in patients who desire treatment. Surg Endosc 37(8):6032\u20136043. https:\/\/doi.org\/10.1007\/s00464-023-10030-z","journal-title":"Surg Endosc"},{"issue":"4","key":"13147_CR23","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.soard.2024.11.002","volume":"21","author":"CS Valukas","year":"2025","unstructured":"Valukas CS, Sanchez J, Vitello DJ, Jones W, Hungness ES, Teitelbaum EN (2025) Influence of referral type and sociodemographic factors on completion of bariatric surgery. Surg Obes Relat Dis 21(4):497\u2013503. https:\/\/doi.org\/10.1016\/j.soard.2024.11.002","journal-title":"Surg Obes Relat Dis"}],"container-title":["Surgical Endoscopy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00464-026-13147-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00464-026-13147-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00464-026-13147-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:17:58Z","timestamp":1789575478000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00464-026-13147-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["13147"],"URL":"https:\/\/doi.org\/10.1007\/s00464-026-13147-z","relation":{},"ISSN":["0930-2794","1432-2218"],"issn-type":[{"value":"0930-2794","type":"print"},{"value":"1432-2218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"28 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Kozato, Ms. Patel, Dr. Massie, Dr. Mankowski, Dr. Ren-Fielding, and Dr. Parikh have no conflicts of interest or financial ties to disclose. Dr. Orandi has previously served on an advisory board for Boehringer Ingelheim unrelated to the submitted work. Dr. Segev has previously received payments from Sanofi, CareDx Inc, Moderna, AstraZeneca, Roche, Optum, Organ Ox, Hansa, Biosidus, and Springer unrelated to the submitted work. Dr. Chhabra has received payments from GI Windows Surgical unrelated to the\u00a0submitted\u00a0work.","order":1,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Declarations"}}]}}